Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.

Antimicrobial Agents and Chemotherapy
Motokazu MukaideMasashi Mizokami

Abstract

The mechanism by which entecavir resistance (ETVr) substitutions of hepatitis B virus (HBV) can induce breakthrough (BT) during ETV therapy is largely unknown. We conducted a cross-sectional study of 49 lamivudine (LVD)-refractory patients and 59 naïve patients with chronic hepatitis B. BT was observed in 26.8% of the LVD-refractory group during weeks 60 to 144 of ETV therapy. A line probe assay revealed ETVr substitutions only in the LVD-refractory group, i.e., in 4.9% of patients at baseline, increasing to 14.6%, 24.4%, and 44.8% at weeks 48, 96, and 144, respectively. Multivariate logistic regression analysis adjusted for age, gender, HBV DNA levels, and LVD resistance (LVDr) (L180M and M204V, but not M204I) indicated that T184 substitutions and S202G (not S202C) were a significant factor for BT (adjusted odds ratio [OR], 141.12, and 95% confidence interval [CI], 6.94 to 2,870.20; OR, 201.25, and 95% CI, 11.22 to 3608.65, respectively). Modeling of HBV reverse transcriptase (RT) by docking simulation indicated that a combination of LVDr and ETVr (T184L or S202G) was characterized by a change in the direction of the D205 residue and steric conflict in the binding pocket of ETV triphosphate (ETV-TP), by significantly longer mi...Continue Reading

References

Oct 5, 1990·Journal of Molecular Biology·S F AltschulD J Lipman
Dec 11, 1997·The New England Journal of Medicine·W M Lee
Dec 22, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E OritoS Iino
Aug 2, 2001·Journal of Molecular Biology·Z Xiang, B Honig
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Zhexin XiangBarry Honig
Dec 23, 2003·Intervirology·Yuzo Miyakawa, Masashi Mizokami
Apr 2, 2005·Alimentary Pharmacology & Therapeutics·M-F YuenC-L Lai
Mar 10, 2006·The New England Journal of Medicine·Ching-Lung LaiUNKNOWN BEHoLD AI463027 Study Group
Jun 10, 2006·Gastroenterology·Morris ShermanUNKNOWN AI463026 BEHoLD Study Group
Aug 31, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hyung Joon YimAnna S F Lok
Mar 12, 2008·Journal of Hepatology·Stéphanie VilletFabien Zoulim
Apr 26, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Carl J BaldickRichard J Colonno
Oct 11, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Emmet B KeeffeHillel Tobias
Mar 13, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Daniel J TenneyRichard J Colonno

❮ Previous
Next ❯

Citations

Mar 13, 2014·The Journal of Infectious Diseases·Danny Ka-Ho WongMan-Fung Yuen
Mar 10, 2012·Medicina clínica·Carmen Hidalgo-TenorioFederico García
Oct 2, 2012·Journal of Medical Virology·Guan Huei LeeSeng Gee Lim
May 19, 2011·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Kentaro MatsuuraMasashi Mizokami
Oct 15, 2013·Fundamental & Clinical Pharmacology·Li-Peng QiuKe-Ping Chen
Apr 16, 2015·Liver International : Official Journal of the International Association for the Study of the Liver·Young E ChonKwang-Hyub Han
Mar 31, 2015·Journal of Hepatology·Sanae HayashiYasuhito Tanaka
Apr 26, 2012·The International Journal of Biochemistry & Cell Biology·Eleftherios MichailidisStefan G Sarafianos
May 13, 2014·Current Opinion in Virology·Luis Menéndez-AriasBeatriz Pacheco
Apr 22, 2015·Future Virology·Daniel N Clark, Jianming Hu
Apr 5, 2014·The Journal of Organic Chemistry·Uma S SinghChung K Chu
Sep 6, 2018·Biomédica : revista del Instituto Nacional de Salud·Dioselina Peláez-CarvajalJosé Aldemar Usme-Ciro
Apr 4, 2015·World Journal of Gastroenterology : WJG·Hong-Yu JiaYi-Da Yang
Jun 17, 2020·Antimicrobial Agents and Chemotherapy·Katherine E SquiresAbel De La Rosa
Sep 12, 2020·PloS One·Cynthia Raissa Tamandjou TchuemMonique Ingrid Andersson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.